Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  paclitaxel albumin-stabilized nanoparticle formulation
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 128 for your search:
Start Over
Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 65 and over
Sponsor: Other
Protocol IDs: GBG 52, 2008-003995-23, NCT01204437
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA031, NCT00540514
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: INST 0553C, NCI-2012-00946, NCT00659269
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00476, CTSU 40502, NCCTG N063H, CDR0000617539, CALGB 40502, U10CA031946, U10CA180821, NCT00785291
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA046, NCT00844649
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA033, NCT00864253
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11-PIR-11, NCT01492101
Study Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 69, 2011-004714-41, NCT01583426
Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: FM-12-B01, 2012-003481-41, NCT01822314
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA015, NCT00073723
Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA040, NCT00398086
Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: DOXIL, NCT00442260
Abraxane and Alimta in Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000542904, UCD-185, UCDCC-185, UCD-200614714, NCT00470548
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 07-069, NCT00570674
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Cisplatin, and Cetuximab Given Together With Radiation Therapy in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: CDR0000634258, SCCC-112008-019, ABX 236-HN08US, 112008-019, NCT00851877
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 040803, P30CA072720, CDR0000648116, 0220090058, CRAD001C2448;, NCI-2012-00547, CINJ-040803, NOVARTIS-CINJ-040803, NCT00934895
Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: NAB-PTX-GC, NCT01336062
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 201204071, NCT01555853
Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: ABXDDP20101224, NCT01735409
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-01425, E1213, EA2131, U10CA180820, U10CA021115, NCT02194829
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA013-0, NCT00046514
Phase II Study of ABI-007, Carboplatin, and Trastuzumab (Herceptin®) in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MSKCC-04018, ABI-CA016, NCT00085605
ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000423195, U10CA025224, N0531, 855-05, N0433, NCCTG-N0531, NCT00110084
Start Over